PHP
LFCR icon

Parkman Healthcare Partners’s Lifecore Biomedical LFCR Stock Holding History

Parkman Healthcare Partners’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-203,578
Closed -$1.32M – 90
2022
Q4 		$1.32M Buy
203,578
+1,330
+0.7% +$11K 0.35% 68
2022
Q3 		$1.8M Buy
202,248
+80,630
+66% +$820K 0.51% 61
2022
Q2 		$1.21M Buy
121,618
+6,302
+5% +$62.4K 0.45% 55
2022
Q1 		$1.33M Buy
+115,316
New +$1.28M 0.39% 58

Other funds holding LFCR

GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Parkman Healthcare Partners's LFCR Position: Q1 2023 in Review

Parkman Healthcare Partners sold out of Lifecore Biomedical (LFCR) in Q1 2023, closing a stake of 203,578 shares — an estimated $1.32M sold.

Parkman Healthcare Partners first reported a position in LFCR in Q1 2022 and held it in 4 quarters. The position peaked at $1.8M in Q3 2022. 82 funds tracked by Wall St. Rank hold LFCR as of Q1 2023.

  • Parkman Healthcare Partners reported no remaining Lifecore Biomedical position as of Q1 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 203,578 Lifecore Biomedical shares in Q1 2023, an estimated $1.32M.
  • Parkman Healthcare Partners first reported a position in Lifecore Biomedical in Q1 2022 and held it in 4 quarters.
  • Parkman Healthcare Partners's Lifecore Biomedical position peaked at $1.8M in Q3 2022.
  • 82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2023.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.